Patents by Inventor Hans Sidén

Hans Sidén has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liquid pharmaceutical composition comprising nitisinone
    Patent number: 9301932
    Abstract: The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: April 5, 2016
    Assignee: SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB
    Inventors: Lennart Svensson, Hans Sidén
  • LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE
    Publication number: 20150174081
    Abstract: The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I.
    Type: Application
    Filed: March 5, 2015
    Publication date: June 25, 2015
    Inventors: Lennart SVENSSON, Hans SIDEN
  • LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE
    Publication number: 20140206771
    Abstract: The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I.
    Type: Application
    Filed: June 20, 2012
    Publication date: July 24, 2014
    Applicant: Swedish Orphan Biovitrum International AB
    Inventors: Lennart Svensson, Hans Sidén